Trial Profile
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Vonlerolizumab (Primary)
- Indications Advanced breast cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 14 Jun 2022 Results published in the Clinical Cancer Research
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 3 Dec 2019 to 10 Jan 2020.